MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Endocrine Peptide platform to design engineered peptides intended to provide targeted activity, extended duration and more consistent treatment effects.

MBX’s lead program, MBX 1416, is an investigational long-acting parathyroid hormone receptor agonist being developed as a potential replacement therapy for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone. The company’s broader pipeline is focused on additional peptide-based medicines for endocrine diseases with significant unmet treatment needs.

Headquartered in Indianapolis, Indiana, MBX Biosciences is advancing its programs through clinical development and regulatory evaluation. Its therapies are intended for patients in markets where endocrine disorders are treated with approved pharmaceutical products, although specific commercial geographies will depend on future clinical results and regulatory authorizations.

Key Stats

• Today's Range: $56.90 to $61.12
• 50-Day Range: $53.63 to $70.70
• 52-Week Range: $12.94 to $72.64
• Volume: 637,306 shs
• Average Volume: 533,366 shs
• Market Capitalization: $2.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $83.89
• Consensus Rating: Moderate Buy

MBX Biosciences Stock Analysis - MarketRank™

MBX Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 392nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

MBX Biosciences has a consensus price target of $83.89, representing about 43.4% upside from its current price of $58.51.

Amount of Analyst Coverage

MBX Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MBX Biosciences are expected to decrease in the coming year, from ($3.10) to ($4.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MBX Biosciences is -24.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MBX Biosciences is -24.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MBX Biosciences has a P/B Ratio of 7.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.44% of the float of MBX Biosciences has been sold short.

Short Interest Ratio / Days to Cover

MBX Biosciences has a short interest ratio ("days to cover") of 11.44, which indicates bearish sentiment.

Change versus previous month

Short interest in MBX Biosciences has recently decreased by 0.62%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MBX Biosciences does not currently pay a dividend.

Dividend Growth

MBX Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.11

News Sentiment

MBX Biosciences has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for MBX Biosciences this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for MBX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

1 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,335.00 in company stock.

Percentage Held by Insiders

31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

MBX Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MBX
• Previous Symbol: NASDAQ:MBX
• CIK: 1776111
• Web: mbxbio.com
• Phone: (317) 989-3100
• Fax: N/A
• Employees: 63
• Year Founded: 2018

Price Target and Rating

• Average Price Target for MBX Biosciences: $83.89
• High Price Target: $150.00
• Low Price Target: $18.00
• Potential Upside/Downside: +43.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.02%
• Return on Assets: -24.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.08
• Quick Ratio: 18.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.22 per share
• Price / Book: 7.12

Miscellaneous

• Outstanding Shares: 48,160,000
• Free Float: 33,187,000
• Market Cap: $2.82 billion
• Optionable: N/A
• Beta: 0.10